Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology No. 59. 2016 Authors' conclusions The combined use of afatinib and paclitaxel for this indication has been investigated in the LUX–Lung 5 trial, a randomised, open-label phase III study. Although the study shows a significant gain in median PFS, the treatment with afatinib–paclitaxel is associated with a higher expanse of AEs and relatively high costs. In addition, more data will be required due to the unexpected low number of enrolled patients and the subsequent lower power of the study. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32016000988 Date abstract record published 14/09/2016 |